Zhejiang Anglikang Pharmaceutical Co Ltd Class A (002940) - Net Assets
Based on the latest financial reports, Zhejiang Anglikang Pharmaceutical Co Ltd Class A (002940) has net assets worth CN¥1.83 Billion CNY (≈ $267.16 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.92 Billion ≈ $427.51 Million USD) and total liabilities (CN¥1.10 Billion ≈ $160.35 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 002940 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.83 Billion |
| % of Total Assets | 62.49% |
| Annual Growth Rate | 23.54% |
| 5-Year Change | 30.51% |
| 10-Year Change | 580.71% |
| Growth Volatility | 40.7 |
Zhejiang Anglikang Pharmaceutical Co Ltd Class A - Net Assets Trend (2014–2024)
This chart illustrates how Zhejiang Anglikang Pharmaceutical Co Ltd Class A's net assets have evolved over time, based on quarterly financial data. Also explore Zhejiang Anglikang Pharmaceutical Co Ltd assets under control for the complete picture of this company's asset base.
Annual Net Assets for Zhejiang Anglikang Pharmaceutical Co Ltd Class A (2014–2024)
The table below shows the annual net assets of Zhejiang Anglikang Pharmaceutical Co Ltd Class A from 2014 to 2024. For live valuation and market cap data, see 002940 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.80 Billion ≈ $263.17 Million |
-1.85% |
| 2023-12-31 | CN¥1.83 Billion ≈ $268.12 Million |
+11.31% |
| 2022-12-31 | CN¥1.65 Billion ≈ $240.88 Million |
+11.61% |
| 2021-12-31 | CN¥1.47 Billion ≈ $215.83 Million |
+7.04% |
| 2020-12-31 | CN¥1.38 Billion ≈ $201.64 Million |
+35.56% |
| 2019-12-31 | CN¥1.02 Billion ≈ $148.74 Million |
+4.69% |
| 2018-12-31 | CN¥970.93 Million ≈ $142.08 Million |
+146.20% |
| 2017-12-31 | CN¥394.37 Million ≈ $57.71 Million |
+20.44% |
| 2016-12-31 | CN¥327.43 Million ≈ $47.91 Million |
+23.93% |
| 2015-12-31 | CN¥264.20 Million ≈ $38.66 Million |
+21.70% |
| 2014-12-31 | CN¥217.08 Million ≈ $31.77 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Zhejiang Anglikang Pharmaceutical Co Ltd Class A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 65147305316.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥642.71 Million | 41.99% |
| Common Stock | CN¥201.73 Million | 13.18% |
| Other Comprehensive Income | CN¥115.45 Million | 7.54% |
| Other Components | CN¥570.66 Million | 37.28% |
| Total Equity | CN¥1.53 Billion | 100.00% |
Zhejiang Anglikang Pharmaceutical Co Ltd Class A Competitors by Market Cap
The table below lists competitors of Zhejiang Anglikang Pharmaceutical Co Ltd Class A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nabors Industries Ltd
F:NBI1
|
$977.03 Million |
|
Daishin Sec
KO:003540
|
$977.81 Million |
|
Ningbo Donly Co Ltd
SHE:002164
|
$978.09 Million |
|
ALPHAMAB ONCOLO.DL-000002
F:3NK
|
$978.26 Million |
|
Biotest Aktiengesellschaft
XETRA:BIO
|
$976.15 Million |
|
Triveni Engineering & Industries Limited
NSE:TRIVENI
|
$975.92 Million |
|
Qisda Corp
TW:2352
|
$975.88 Million |
|
Brookline Bancorp Inc
NASDAQ:BRKL
|
$975.70 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zhejiang Anglikang Pharmaceutical Co Ltd Class A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,586,203,386 to 1,530,549,492, a change of -55,653,894 (-3.5%).
- Net income of 80,334,514 contributed positively to equity growth.
- Dividend payments of 58,767,933 reduced retained earnings.
- Share repurchases of 54,375,445 reduced equity.
- Other comprehensive income increased equity by 10,272,546.
- Other factors decreased equity by 33,117,576.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥80.33 Million | +5.25% |
| Dividends Paid | CN¥58.77 Million | -3.84% |
| Share Repurchases | CN¥54.38 Million | -3.55% |
| Other Comprehensive Income | CN¥10.27 Million | +0.67% |
| Other Changes | CN¥-33.12 Million | -2.16% |
| Total Change | CN¥- | -3.51% |
Book Value vs Market Value Analysis
This analysis compares Zhejiang Anglikang Pharmaceutical Co Ltd Class A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.32x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 26.10x to 4.32x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | CN¥1.27 | CN¥33.08 | x |
| 2015-12-31 | CN¥1.75 | CN¥33.08 | x |
| 2016-12-31 | CN¥2.19 | CN¥33.08 | x |
| 2017-12-31 | CN¥2.61 | CN¥33.08 | x |
| 2018-12-31 | CN¥6.15 | CN¥33.08 | x |
| 2019-12-31 | CN¥5.10 | CN¥33.08 | x |
| 2020-12-31 | CN¥6.94 | CN¥33.08 | x |
| 2021-12-31 | CN¥6.78 | CN¥33.08 | x |
| 2022-12-31 | CN¥7.57 | CN¥33.08 | x |
| 2023-12-31 | CN¥7.91 | CN¥33.08 | x |
| 2024-12-31 | CN¥7.66 | CN¥33.08 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zhejiang Anglikang Pharmaceutical Co Ltd Class A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.25%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.31%
- • Asset Turnover: 0.51x
- • Equity Multiplier: 1.94x
- Recent ROE (5.25%) is below the historical average (15.88%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 27.77% | 7.36% | 0.93x | 4.05x | CN¥32.08 Million |
| 2015 | 25.87% | 8.27% | 0.97x | 3.23x | CN¥39.28 Million |
| 2016 | 26.44% | 12.24% | 0.92x | 2.34x | CN¥51.10 Million |
| 2017 | 27.31% | 11.58% | 0.96x | 2.45x | CN¥64.07 Million |
| 2018 | 11.83% | 8.66% | 0.85x | 1.60x | CN¥16.79 Million |
| 2019 | 11.63% | 8.04% | 1.01x | 1.44x | CN¥15.76 Million |
| 2020 | 12.41% | 12.69% | 0.66x | 1.47x | CN¥31.83 Million |
| 2021 | 8.95% | 8.68% | 0.66x | 1.56x | CN¥-14.04 Million |
| 2022 | 8.47% | 8.12% | 0.60x | 1.73x | CN¥-22.97 Million |
| 2023 | 8.72% | 8.54% | 0.54x | 1.90x | CN¥-20.25 Million |
| 2024 | 5.25% | 5.31% | 0.51x | 1.94x | CN¥-72.72 Million |
Industry Comparison
This section compares Zhejiang Anglikang Pharmaceutical Co Ltd Class A's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $1,347,197,696
- Average return on equity (ROE) among peers: 4.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zhejiang Anglikang Pharmaceutical Co Ltd Class A (002940) | CN¥1.83 Billion | 27.77% | 0.60x | $976.49 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $2.84 Billion | -41.97% | 9.13x | $1.22 Billion |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $638.89 Million | 0.88% | 0.70x | $438.59 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $1.05 Billion | 10.46% | 0.19x | $5.18 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $1.07 Billion | 3.83% | 0.46x | $2.81 Billion |
| Wedge Industrial Co Ltd (000534) | $1.29 Billion | 11.69% | 1.47x | $2.95 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $13.85 Billion |
| Hainan Haiyao Co Ltd (000566) | $5.08 Billion | 1.71% | 1.08x | $949.23 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $141.91 Million | 11.01% | 0.32x | $391.07 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $994.58 Million | 2.01% | 2.11x | $1.03 Billion |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $332.48 Million | 26.89% | 0.68x | $3.30 Billion |
About Zhejiang Anglikang Pharmaceutical Co Ltd Class A
Zhejiang AngLiKang Pharmaceutical CO.,LTD., a pharmaceutical company, engages in manufacturing APIs and pharmaceutical preparations for oral cephalosporins, cardiovascular, and kidney diseases. The company also offers products in the areas of anti-infection, cardiovascular, urinary system (nephropathy), anesthesia and pain, and anti-androgen. The company was founded in 2001 and is based in Shengz… Read more